Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 341,188
  • Shares Outstanding, K 67,562
  • Annual Sales, $ 7,360 K
  • Annual Income, $ -52,090 K
  • 60-Month Beta 0.07
  • Price/Sales 48.23
  • Price/Cash Flow N/A
  • Price/Book 1.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.26
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -31.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.89 +3.27%
on 09/04/19
5.83 -13.38%
on 08/19/19
-0.41 (-7.51%)
since 08/13/19
3-Month
4.89 +3.27%
on 09/04/19
6.00 -15.83%
on 06/14/19
-0.66 (-11.56%)
since 06/13/19
52-Week
3.25 +55.38%
on 01/30/19
12.50 -59.60%
on 12/12/18
-3.36 (-39.95%)
since 09/13/18

Most Recent Stories

More News
AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson's Disease Diagnostic Imaging Agent

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced The Michael J. Fox Foundation for Parkinson's...

ACIU : 5.05 (-3.81%)
AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update

AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced its business and clinical plan and strategy,...

ACIU : 5.05 (-3.81%)
AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced a research partnership with leading scientists...

ACIU : 5.05 (-3.81%)
Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACIU : 5.05 (-3.81%)
AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer's Disease

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the initiation of a Phase 1b/2a clinical...

ACIU : 5.05 (-3.81%)
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer(TM), an Investigational Treatment for Alzheimer's Disease

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small...

ACIU : 5.05 (-3.81%)
LLY : 110.89 (-0.52%)
AC Immune Announces Election of New Chairman of the Board at Annual General Meeting

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced that shareholders in the Company have elected...

ACIU : 5.05 (-3.81%)
AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer's in Down Syndrome

AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering precision medicine in neurodegenerative diseases, today announced that it...

ACIU : 5.05 (-3.81%)
AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer's Disease

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Genentech, a member of the Roche Group,...

ACIU : 5.05 (-3.81%)
AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ACIU : 5.05 (-3.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ACIU with:

Business Summary

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta...

See More

Key Turning Points

2nd Resistance Point 5.54
1st Resistance Point 5.29
Last Price 5.05
1st Support Level 4.90
2nd Support Level 4.76

See More

52-Week High 12.50
Fibonacci 61.8% 8.97
Fibonacci 50% 7.88
Fibonacci 38.2% 6.78
Last Price 5.05
52-Week Low 3.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar